Prograf Capsules and Injection (Astellas), Drug Reference Encyclopedia | DRUGS INDEX | MANUFACTURERS INDEX | HEALTH | ANATOMY | GEOGRAPHY | USA STATISTICS | CHINA STATISTICS | JOBS | Increased susceptibility to infection and the possible development of lymphoma may result from immunosuppression. Only physicians experienced in immunosuppressive therapy and management of organ transplant patients should prescribe Prograf. Patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The physician responsible for maintenance therapy should have complete information requisite for the follow-up of the patient. As in patients receiving other immunosuppressants, patients receiving Prograf are at increased risk of developing lymphomas and other malignancies, particularly of the skin. The risk appears to be related to the intensity and duration of immunosuppression rather than to the use of any specific agent. A lymphoproliferative disorder (LPD) related to Epstein-Barr Virus (EBV) infection has been reported in immunosuppressed organ transplant recipients. The risk of LPD appears greatest in young children who are at risk for primary EBV infection while immunosuppressed or who are switched to Prograf following long-term immunosuppression therapy. Because of the danger of oversuppression of the immune system which can increase susceptibility to infection, combination immunosuppressant therapy should be used with caution. {1} Release: Clinical Studies Demonstrate Once-Daily Modified Release Prograf(R) Formula To Be Promising Treatment Option - News, Search Jobs, Events SEATTLE, May 24 /PRNewswire/ -- Two studies presented today at the 6th American Transplant Congress (ATC) demonstrate the safety and efficacy of once-daily Modified Release (MR) Prograf (TAC or tacrolimus) as compared to standard Prograf.
